Klépierre : The downward trend should continue
Entry price | Target | Stop-loss | Potential |
---|
€29.17 |
€26.5 |
€31.6 |
+9.15% |
---|
The declining trend in the stock price that has been seen for a number of trading sessions, should not be expected to reach a turning point over the coming days.
Summary● In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
● For a short-term investment strategy, the company has poor fundamentals.
Strengths● Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
● This company will be of major interest to investors in search of a high dividend stock.
Weaknesses● According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
● One of the major weak points of the company is its financial situation.
● The group usually releases earnings worse than estimated.
● The company's "enterprise value to sales" ratio is among the highest in the world.
● For the past year, analysts have significantly revised downwards their profit estimates.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.